InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

- Current share price for ATX : $0.155

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$80 FDA Fast Track Designation for Narmafotinib 20 Sep 2024 8:39AM $0.099 $0.155 risen by 56.57%
$80 Change of Director's Interest Notice - Dr Chris Burns 26 Aug 2024 4:25PM $0.125 $0.155 risen by 24%
$80 Application for quotation of securities - ATX 26 Aug 2024 3:59PM $0.125 $0.155 risen by 24%
$80 Results of Annual General Meeting 23 Aug 2024 11:40AM $0.125 $0.155 risen by 24%
$80 Managing Director AGM Presentation 23 Aug 2024 10:05AM $0.130 $0.155 risen by 19.23%
$80 Fifth Confirmed Response in ACCENT Trial 21 Aug 2024 9:32AM $0.130 $0.155 risen by 19.23%
$80 Change in substantial holding 12 Aug 2024 5:30PM $0.130 $0.155 risen by 19.23%
$80 Amplia Receives R&D Tax Rebate Totalling $3.2 Million 12 Aug 2024 9:08AM $0.130 $0.155 risen by 19.23%
$80 Ceasing to be a substantial holder from SOL 9 Aug 2024 3:26PM $0.135 $0.155 risen by 14.81%
$80 Ceasing to be a substantial holder from PCG 8 Aug 2024 1:46PM $0.125 $0.155 risen by 24%
$80 Granting of Key Patent in Europe and Japan 7 Aug 2024 10:17AM $0.140 $0.155 risen by 10.71%
$80 Additional Patient Response in Pancreatic Cancer Trial 6 Aug 2024 8:39AM $0.090 $0.155 risen by 72.22%
$80 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2024 8:13AM $0.086 $0.155 risen by 80.23%
$80 Sustained Reduction in Tumour Size Seen In Pancreatic Trial 25 Jul 2024 1:04PM $0.062 $0.155 risen by 150%
$80 Proposed issue of securities - ATX 22 Jul 2024 4:23PM $0.061 $0.155 risen by 154.10%
$80 Notice of Annual General Meeting/Proxy Form 22 Jul 2024 3:44PM $0.061 $0.155 risen by 154.10%
$80 Section 708A Cleansing Notice 19 Jul 2024 5:18PM $0.061 $0.155 risen by 154.10%
$80 Application for quotation of securities - ATX 19 Jul 2024 4:47PM $0.061 $0.155 risen by 154.10%
$80 Proposed issue of securities - ATX 17 Jul 2024 5:12PM $0.064 $0.155 risen by 142.19%
$80 Application for quotation of securities - ATX 17 Jul 2024 4:38PM $0.064 $0.155 risen by 142.19%
$80 Bioshares Conference Presentation 12 Jul 2024 8:24AM $0.060 $0.155 risen by 158.33%
$80 First 26 Patients recruited in Phase 2A ACCENT Trial 3 Jul 2024 9:54AM n/a $0.155 n/a
$80 Annual General Meeting to be held Friday 23 August 2024 2 Jul 2024 5:38PM n/a $0.155 n/a
$80 Notification of cessation of securities - ATX 25 Jun 2024 4:14PM $0.058 $0.155 risen by 167.24%
$80 Change of Director's Interest Notice - Dr Robert Peach 20 Jun 2024 4:11PM $0.061 $0.155 risen by 154.10%

151 - 175 of 538 results

Page 7 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.